Dr. Kim Ann Saal

Publications of Kim Ann Saal

Boron-Containing Probes for Non-Optical High-Resolution Imaging of Biological Samples.

Kabatas S, Agüi-Gonzales P, Saal KA, Jähne S, Opazo F, Rizzoli SO, Phan TNN. 
Angew Chem Int Ed Engl. 2019 Mar 11;58(11):3438-3443. doi: 10.1002/anie.201812032. Epub 2019 Feb 6.
View at PubMed


Boron-Containing Probes for Non-Optical High-Resolution Imaging of Biological Samples.

Kabatas S, Agüi-Gonzales P, Saal KA, Jähne S, Opazo F, Rizzoli SO, Phan TNN. 
Angew Chem 2019 Mar 11;131(11):3476-3481. doi:10.1002/anie.201812032. Epub 2019 Jan 7.


ROCK inhibition in models of neurodegeneration and its potential for clinical translation.

Koch JC, Tatenhorst L, Roser AE, Saal KA, Tönges L, Lingor P. 
Pharmacol Ther. 2018 Sep;189:1-21. doi: 10.1016/j.pharmthera.2018.03.008. Epub 2018 Apr 3.
View at PubMed


Combined Use of Unnatural Amino Acids Enables Dual-Color Super-Resolution Imaging of Proteins via Click Chemistry.

Saal KA, Richter F, Rehling P, Rizzoli SO. 
ACS Nano. 2018 Dec 26;12(12):12247-12254. doi: 10.1021/acsnano.8b06047. Epub 2018 Dec 13.
View at PubMed


Altered expression of growth associated protein-43 and rho kinase in human patients with Parkinson´s disease.

Saal KA, Galter D, Roeber S, Bähr M, Tönges L, Lingor P.
Brain Pathol. 2016 Jan 8. doi: 10.1111/bpa.12346.
View at PubMed


AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson’s disease in vitro and in vivo.

Saal KA, Koch JC, Tatenhorst L, Szegő EM, Ribas VT, Michel U, Bähr M, Tönges L, Lingor P.
Neurobiol Dis. 2015 Jan;73:150-62. doi: 10.1016/j.nbd.2014.09.013. Epub 2014 Oct 2.
View at PubMed


The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice.

Günther R, Saal KA, Suhr M, Scheer D, Koch JC, Bähr M, Lingor P, Tönges L.
Front Neurosci. 2014 Oct 7;8:304. doi: 10.3389/fnins.2014.00304. eCollection 2014.
View at PubMed

Alpha-synuclein mutations impair axonal regeneration in models of Parkinson’s disease.

Tönges L, Szegö EM, Hause P, Saal KA, Tatenhorst L, Koch JC, D Hedouville Z, Dambeck V, Kügler S, Dohm CP, Bähr M, Lingor P.
Front Aging Neurosci. 2014 Sep 10;6:239. doi: 10.3389/fnagi.2014.00239. eCollection 2014.
View at PubMed


Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.

Tatenhorst L, Tönges L, Saal KA, Koch JC, Szegő ÉM, Bähr M, Lingor P.
J Neuropathol Exp Neurol. 2014 Aug;73(8):770-9. doi: 10.1097/NEN.0000000000000095.
View at PubMed


Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.

Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal KA, Barski E, Nientied T, Götz AA, Koch JC, Mueller BK, Weishaupt JH, Sereda MW, Hanisch UK, Bähr M, Lingor P.
Glia. 2014 Feb;62(2):217-32. doi: 10.1002/glia.22601. Epub 2013 Dec 6.
View at PubMed


Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease.

Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego ÉM, Bähr M, Weishaupt JH, Lingor P.
Brain. 2012 Nov;135(Pt 11):3355-70. doi: 10.1093/brain/aws254. Epub 2012 Oct 19.
View at Pubmed

Copyright 2013 - 2019 | rizzoli-lab.de